<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>2811498</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Martínez, R</dc:author>
<dc:author>García Díez, I</dc:author>
<dc:author>Palomera, L</dc:author>
<dc:description xml:lang="en">Two cases of myelofibrosis are reported, one corresponding to a chronic idiopathic myelofibrosis and another to an acute myelofibrosis or megakaryoblastic leukemia (AMGL). According to current knowledge, the origin of fibrosis in these disorders is a megakaryoblastic/megakaryocytic proliferation in the bone marrow. These megakaryocytic clonal populations result in an ineffective megakaryocytopoiesis and in an inability to store beta-thromboglobulin (BTG), platelet factor 4 (PlF4) and platelet derived growth factor (PDGF) in the alpha granules, whereby their release is increased. Both PDGF, a powerful stimulator of fibroblastic activity, and PlF4, a collagenase inhibitor, cooperate in the development of myelofibrosis. Owing to its action inducing cellular differentiation towards the monocytic-macrophagic line, which secretes collagenases and inhibits megakaryocyte proliferation, treatment with 1,25-dihydroxyvitamin D3 was attempted in both cases, 2.5 micrograms daily for 6 months. Satisfactory results were achieved.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>1989 Sep 16 </dc:date>
<dc:title xml:lang="es">Efecto beneficioso de la 1,25-dihidroxivitamina D3 en el tratamiento de la mielofibrosis.</dc:title>
<dc:title xml:lang="en">[Beneficial effect of 1,25-dihydroxyvitamin D3 in the treatment of myelofibrosis].</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
